SCHEMBL5347335

SCHEMBL5347335

NC[C@H](O)[CH]Cc1ccccc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 1/20 0.44
LOXL2 Q9Y4K0 2/20 0.41
CA1 P00915 1/20 0.39
CA2 P00918 1/20 0.39
ARG2 P78540 1/20 0.39
SLC6A2 P23975 1/20 0.38
SLC6A4 P31645 1/20 0.38
SLC6A3 Q01959 1/20 0.38
HTR2A P28223 2/20 0.38
TAAR1 Q96RJ0 2/20 0.38
CYP2A6 P11509 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
KCNH2 Q12809 1/20 0.38
TOP1 P11387 1/20 0.37
EPHX1 P07099 1/20 0.37
IDO1 P14902 3/20 0.36
NOS3 P29474 1/20 0.36
NOS1 P29475 1/20 0.36
NOS2 P35228 1/20 0.36
TSHR P16473 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27628278 1.00 MAOB (0.44) MAOBLOXL2CA1CA2ARG2
SCHEMBL10755711 0.81 MAOB (0.46) MAOBCA1CA2ARG2TOP1
SCHEMBL28081332 0.79 MAOB (0.44) MAOBCA1CA2ARG2SLC6A3
SCHEMBL27459959 0.79 MAOB (0.44) MAOBCA1CA2ARG2SLC6A3
SCHEMBL3295725 0.79 TRPA1 (0.46) MAOBCA1CA2ARG2SMN1; SMN2
SCHEMBL4155331 0.74 MAOB (0.48) MAOBCA1CA2ARG2SLC6A2
SCHEMBL3295095 0.74 MAOB (0.48) MAOBCA1CA2ARG2SLC6A2
SCHEMBL8577158 0.74 MAOB (0.48) MAOBCA1CA2ARG2TOP1
SCHEMBL5219600 0.73 ANPEP (0.46) IDO1
SCHEMBL28026869 0.72 EPHX1 (0.46) MAOBTOP1EPHX1IDO1NOS3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070213407-A1 Compounds to treat Alzheimer's disease ELAN PHARMACEUTICALS AND PHARMACIA & UPJOHN COMPANY LLC 2007-09-13 US disclosed
US-7214715-B2 Compounds to treat Alzheimer's disease PHARMACIA & UPJOHN (US) 2007-05-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070213407-A1 Compounds to treat Alzheimer's disease PSEN2, PSEN1, CHAT MAOB 14/4885LOXL2 2394/4885CA1 396/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.